The stock has a 36-month beta value of -0.91. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for COEP is 28.42M, and at present, short sellers hold a 0.38% of that float. On October 15, 2024, the average trading volume of COEP was 235.65K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
COEP) stock’s latest price update
Coeptis Therapeutics Holdings Inc (NASDAQ: COEP)’s stock price has soared by 13.74 in relation to previous closing price of 0.18. Nevertheless, the company has seen a gain of 20.12% in its stock price over the last five trading days. prnewswire.com reported 2024-09-19 that WEXFORD, Pa., Sept. 19, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that it has received a notification letter from the Nasdaq Hearings Panel (the “Panel”) granting its request for continued listing on The Nasdaq Stock Market (“Nasdaq”) through January 15, 2025, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2).
COEP’s Market Performance
Coeptis Therapeutics Holdings Inc (COEP) has seen a 20.12% rise in stock performance for the week, with a 8.18% gain in the past month and a -32.65% plunge in the past quarter. The volatility ratio for the week is 8.85%, and the volatility levels for the past 30 days are at 8.10% for COEP. The simple moving average for the past 20 days is 16.42% for COEP’s stock, with a -40.93% simple moving average for the past 200 days.
COEP Trading at 7.47% from the 50-Day Moving Average
After a stumble in the market that brought COEP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.25% of loss for the given period.
Volatility was left at 8.10%, however, over the last 30 days, the volatility rate increased by 8.85%, as shares surge +12.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.39% upper at present.
During the last 5 trading sessions, COEP rose by +20.12%, which changed the moving average for the period of 200-days by -73.56% in comparison to the 20-day moving average, which settled at $0.1749. In addition, Coeptis Therapeutics Holdings Inc saw -74.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COEP starting from Cogley Brian, who purchase 5,000 shares at the price of $0.67 back on Jan 10 ’24. After this action, Cogley Brian now owns 30,000 shares of Coeptis Therapeutics Holdings Inc, valued at $3,350 using the latest closing price.
DeSilva Tara, the Director of Coeptis Therapeutics Holdings Inc, purchase 2,266 shares at $0.58 during a trade that took place back on Jan 12 ’24, which means that DeSilva Tara is holding 32,266 shares at $1,305 based on the most recent closing price.
Stock Fundamentals for COEP
Current profitability levels for the company are sitting at:
- -11.28 for the present operating margin
- 0.33 for the gross margin
The net margin for Coeptis Therapeutics Holdings Inc stands at -10.69. The total capital return value is set at -2.09. Equity return is now at value -356.04, with -170.79 for asset returns.
Based on Coeptis Therapeutics Holdings Inc (COEP), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -4.05. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -56.46.
Currently, EBITDA for the company is -20.49 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 5.54. The receivables turnover for the company is 7.86for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.55.
Conclusion
To sum up, Coeptis Therapeutics Holdings Inc (COEP) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
